Top Story
February 16, 2019
SCOTTSDALE, Ariz. — In the face of the “tidal wave of cancer immunotherapy,” collaboration across disciplines is required to manage immune-related adverse events associated with checkpoint inhibitors, according to a presentation at the Seventh Annual Basic and Clinical Immunology for the Busy Clinician symposium.
“In 2018, there were over 900 new cancer immunotherapies in development, with over 5,000 clinical trials investigating these agents and more than half a million patients being treated with these agents,” Leonard H. Calabrese, DO, vice chairman of rheumatic and immunologic disease at the Cleveland Clinic, told attendees. “Immunotherapy is now a pillar of cancer treatment — it is now ensconced as a part of this therapy.”